A01
Fit
The right mechanism for the right patient — not the most advanced mechanism applied to everyone. Our name carries the idea: medicine is not bound to a fixed formula, it is used as it fits.
About us
No fixed formula. Only what fits.
Promax Bioscience was founded in 2023 to solve one problem well: placing an RNA instruction in the cell that causes disease, safely and at scale.
Our story
Founded around a single delivery bottleneck.
The founding team came from discovery, CMC and clinical operations across Chinese and international biopharma. What they had in common was a repeated experience: genetic medicines that worked in principle and stalled in delivery.
Promax was established in Linyi, Shandong, to take on that bottleneck directly. Rather than building another payload platform, the company focused on the interface — the chemistry that attaches a targeting antibody to a lipid nanoparticle and keeps it intact through formulation, storage and dosing.
That focus produced the Ab-LNP platform: a simplified, stable labelling process, an engineered protein corona, and a modular architecture that lets a new antibody reuse an existing process. Around it, the company built the analytical, AI and manufacturing systems needed to make the platform repeatable.
Mission
“Make precision delivery the default, so that a genetic medicine is defined by the cell it reaches.”
What we hold to
Four principles, borrowed from the name.
B02
Precision
Specificity is the product. Every design decision is judged by whether it narrows the distance between dose and target cell.
C03
Pragmatism
A platform is only real if it transfers. We value processes that can be repeated over results that can only be reproduced by their inventor.
D04
Long view
We are building a decade-long pipeline on a foundation we intend to keep. Patents, data and people are treated as long-lived assets.
Roadmap
Where the platform goes next.
Our development plan moves from platform protection, to payload expansion, to clinical programs. Timelines are internal planning targets and may shift with data.
2025 — 2027
Platform protection
PCT filings covering the Ab-LNP_mRNA conjugation and formulation platform, plus the underlying stable labelling process.
2026 — 2027
Second payload and AI system
Ab-LNP_CRISPR gene-editing platform filings, and development of the in-house AI-driven R&D management system.
2027 — 2029
Development candidates
Advancement of lead programs to candidate selection and IND-enabling studies across cardiovascular, oncology and aging.
2029 — 2032
Clinical stage
IND submissions, early clinical development, and expansion of the pipeline into sgRNA-based programs.
Founding team
People who have taken molecules the whole way.
The founding team combines discovery research, quality systems, project leadership and clinical operations experience from institutions and companies across China and Europe.
Tao Gong
M.Sc.General Manager · Founding Team
Leads company strategy, operations and the build-out of the Ab-LNP platform. Previously project director and R&D quality system lead at Wuxi Noyu Pharmaceutical, project manager at Yangzijiang Pharmaceutical’s Haici Institute, and deputy general manager at Jiangsu Yuexing Pharmaceutical, with earlier research and project roles at Luoxin Pharmaceutical, Nantong Cores Biopharma, WuXi AppTec and the Academy of Military Medical Sciences.
- Strategy
- R&D quality systems
- Project leadership
Ning Shen
Ph.D.Founding Team · Scientific Advisor
Geneticist working at the intersection of human genetics, precision diagnostics and translational research. Director of the He Lin Academician Workstation key laboratory at Nantong Fourth People’s Hospital, director of the Shanghai Zhangjiang–Swiss Joint Laboratory for Precision Detection of Human Toxins, professor at Southern Medical University, and chief scientist at Ruice Precision Medical Detection (Shanghai). Postdoctoral research at EPFL, Ph.D. in genetics from Nanjing University.
- Genetics
- Precision diagnostics
- Translational research
Scientific advisors
Our advisory group supports discovery in oncology, cardiovascular disease and inflammation.
Wencheng Zhang
Professor · Taishan Scholar
Shandong University
Professor and doctoral supervisor at Shandong University; deputy director of the Ministry of Education and National Health Commission Key Laboratory of Cardiovascular Remodelling and Function Research. Research focuses on the molecular mechanisms of cardiovascular and metabolic disease.
Tao Yu
Distinguished Professor · Taishan Scholar
Qingdao University
Distinguished professor and doctoral supervisor at Qingdao University; director of the Centre for Vascular Biology and Regenerative Medicine. Research focuses on the regulatory mechanisms and targeted therapy of cardiovascular disease.
Hongrui Lei
Distinguished Professor
Shenyang Pharmaceutical University
Distinguished professor at Shenyang Pharmaceutical University working in new drug design, with research on the design and synthesis of anti-tumour and anti-fibrotic compounds.
Lei Zhang
Distinguished Professor
Henan University
Distinguished professor at Henan University and Ph.D. from Jinan University, working in anti-tumour pharmacology with a focus on screening and testing of novel anti-tumour drugs.
Where we are
Linyi, Shandong
Laboratory and offices: Room 1126-2, Chuangye Building, corner of Linxi 7th Road (West) and Beiyuan Road, Lanshan District, Linyi, Shandong, China.
- Founded
- 2023
- Headquarters
- Linyi, Shandong, China
- Focus
- Antibody-conjugated LNP-RNA
- Model
- Platform company with in-house process development